Saintmed Public Company Limited (SET: SMD100) has informed the Stock Exchange of Thailand that on January 14, 2025, SMDI Co., Ltd., a wholly-owned subsidiary, signed a Memorandum of Understanding (MOU) with Thammasat University Hospital for the Proton Therapy Cancer Treatment Center Project. This collaboration represents a significant step forward in enhancing Thailand’s medical capabilities and advancing the standard of cancer treatment to meet international benchmarks.
Project Details:
- Investment: Approximately THB 2 billion
- Patient Capacity: Nearly 1,000 cancer patients per year
- Projected Revenue: Over THB 12 billion throughout the 20-year contract duration
- Strategic Importance: The project exemplifies an investment combining economic returns with societal impact, demonstrating the balance between generating business profitability and enhancing public wellbeing.
Advantages of Proton Therapy Technology: Proton Therapy is a cutting-edge cancer treatment technology with advantages over conventional radiation therapy (LINAC), as detailed below:
- Superior Precision: Directly targets cancerous tissues with minimal impact on surrounding healthy tissues.
- Minimal Side Effects: Reduces risks to adjacent organs, enabling faster recovery for patients.
- Optimal for Complex Tumors: Especially effective for brain cancer, pediatric cancer, and tumors located near the heart or spinal cord.
- Improved Quality of Life: Patients can quickly resume their daily activities with enhanced well-being.
Support for Thailand’s Medical Hub Policy:
The Proton Therapy Center Project aligns with the Thai government’s Medical Hub policy, aimed at establishing the country as a leading medical center in the ASEAN region. By introducing world-class treatment innovations, this project will strengthen Thailand’s public health system and attract patients from both domestic and international markets.
Remarks from the Executive Team:
Dr. Wiroj Wasusuttikulkarn, Chief Executive Officer of Saintmed Public Company Limited, stated : “The Proton Therapy Cancer Treatment Center Project is a reflection of our vision to propel Thai healthcare to an international level. We are confident that this center will revolutionize cancer treatment in Thailand and play a crucial role in supporting the country’s development as a Medical Hub in the region by leveraging the most advanced technology available.”
“This investment is a prime example of creating financial returns alongside societal impact, meeting the needs of shareholders while fulfilling our corporate social responsibility.”
Related Projects within the Group:
Previously, SMDX Co., Ltd., another subsidiary, initiated operations for the Sleep Diagnosis Center with 11 beds at the Thammasat University Hospital Medical Center (THAMC). The center is currently undergoing accreditation by the American Accreditation Commission International (AACI) and is expected to commence services by early February.
Saintmed Public Company Limited, now rebranded as SMD Rise Public Company Limited, remains committed to advancing innovations in medical services while investing in projects that deliver positive economic and societal impacts. The company aims to push Thai healthcare to the global stage under the concept of “Building a Hospital Empire, No Hospital Required,” representing a new paradigm in the provision of specialized medical services for both the present and future.
The Proton Therapy Center is expected to be completed and operational within two years, significantly faster than the typical 4-5 years required for similar facilities, thanks to the compact size of the selected equipment, which is currently the most advanced in the industry.
